v3.25.1
Off-balance sheet arrangements narrative (Details)
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
May 30, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]        
Purchase Commitments Related To Projects In Development Phase € 160,900,000     € 239,600,000
Purchase Commitment Related to Shared Services 46,000,000     45,900,000
Purchase Commitment Related to Jyseleca Product Supply Chain 2,600,000     14,200,000
Purchase Commitment Related to Commercial And Medical Affairs 1,700,000     29,900,000
Purchase Commitment Related To Project In Discovery Research Phase 60,900,000     79,000,000
Purchase Commitment Related To Services From Novalix. 41,600,000      
Purchase commitments 272,240,000     € 408,521,000
Commitments With Adaptimmune. | $   $ 465,000,000    
Commitments With Another Pharmaceutical Company € 243,500,000      
Adaptimmune Collaboration [member]        
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]        
Purchase commitment related to R&D funding | $     $ 15,000,000  
Purchase Commitment Related To Option Exercise Fees | $     $ 100,000,000